DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Prostatic Hyperplasia

Intervention: Treatment sequence A (Drug); Treatment sequence B (Drug); Treatment sequence C (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline


This study will be an open-label, randomized, single dose, three way crossover study in healthy male subjects. The aim of the study is to evaluate the pharmacokinetic parameters of two formulations of a fixed dose combination (FDC) capsule of dutasteride and tamsulosin hydrochloride (HCl) (0. 5 milligram [mg]/0. 2 mg) relative to co-administration of dutasteride 0. 5 mg capsules and tamsulosin hydrochloride 0. 2 mg tablets in both the fed and fasted states. Approximately 84 healthy adult male subjects will be enrolled into the study and split into two cohorts (fed and fasted), allowing for approximately 36 subjects to complete each cohort. Subjects from both cohorts will receive single oral doses in 3 treatment periods and be randomized to one of six different treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) wherein A= FDC1: Dutasteride and tamsulosin HCl (0. 5 mg/0. 2 mg), B= FDC2: Dutasteride and tamsulosin HCl (0. 5 mg/0. 2 mg), C= Co-administration of commercial formulations of dutasteride(0. 5mg) and tamsulosin HCl (0. 2mg). Each treatment period will be separated by a minimum 28 day washout period. Blood samples for pharmacokinetic analysis will be taken at regular intervals after dosing. Safety will be assessed by measurement of blood pressure, heart rate and review of adverse events.

Clinical Details

Official title: An Open-label, Randomized, Single Dose, Three-way Crossover Study to Determine the Bioavailability of Two Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg Capsules and Tamsulosin Hydrochloride 0.2mg Tablets in Healthy Male Subjects in the Fed and Fasted States

Study design: Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome:

Area under the curve from 0 to the time of the last quantifiable concentration (AUC[0-t]) of tamsulosin in serum

Area under the curve from 0 to infinity (AUC[0-infinity]) of tamsulosin in serum

Maximum drug concentration (Cmax) of dutasteride in serum

AUC(0-t) of dutasteride in serum

Secondary outcome:

Time to reach maximum serum concentration (tmax) of tamsulosin and dutasteride in serum

Terminal half-life (t½) of tamsulosin in serum (as data permit).

Safety and tolerability as assessed by Vital signs (blood pressure and pulse rate [PR])

Safety and tolerability as assessed by electrocardiogram (ECG) measurements

Safety and tolerability as assessed by review of adverse events (AEs)

Safety and tolerability as assessed by clinical laboratory safety data


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Male.


Inclusion Criteria:

- Males aged between 18 and 65 years of age inclusive, at the time of signing the

informed consent.

- Healthy as determined by a responsible and experienced physician, based on a medical

evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator, in consultation with the GSK Medical Monitor if required, agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.

- Body weight >=50 kilogram (kg) and body mass index (BMI) within the range 18 - 32

kg/m^2 (square meter) (inclusive).

- Male subjects with female partners of child-bearing potential must agree to use a

condom. This criterion must be followed from the time of the first dose of study medication until 50 days post-last dose.

- Capable of giving written informed consent, which includes compliance with the

requirements and restrictions listed in the consent form.

- Able to swallow and retain oral medication.

- Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) <2x (Upper limit

of normal) ULN; alkaline phosphatase and bilirubin <=1. 5xULN (isolated bilirubin >1. 5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).

- Based on single or averaged corrected QT (QTc) values of triplicate

electrocardiograms (ECGs) obtained over a brief recording period: QT duration corrected for heart rate by Fridericia's formula (QTcF) <450 milliseconds (msec) Exclusion Criteria: Criteria Based Upon Medical Histories

- Current or chronic history of liver disease, or known hepatic or biliary

abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

- History of sensitivity to any of the study medications, or components thereof or a

history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation.

- History of postural hypotension, dizziness, poor hydration, vertigo, vaso-vagal

reactions or any other signs and symptoms of orthostasis, which in the opinion of the investigator could be exacerbated by tamsulosin and result in putting the subject at risk of injury.

- History of regular alcohol consumption within 6 months of the study defined for US

sites as: an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram (g) of alcohol: 12 ounces (360 millilitre [mL]) of beer, 5 ounces (150 mL) of wine or 1. 5 ounces (45 mL) of 80 proof distilled spirits.

- History of diabetes or peptic ulcer disease which is uncontrolled by medical


- History of breast cancer or clinical breast examination finding suggestive of

malignancy. History of malignancy within the past five years, except for basal cell carcinoma of the skin. Subjects with a prior malignancy who have had no evidence of disease for at least the past 5 years are eligible.

- Prior medical history or evidence of prostate cancer (e. g., positive biopsy, or

suspicious ultrasound, or suspicious digital rectal examination [DRE]). Patients with suspicious ultrasound or DRE who have had a negative biopsy within the preceding 6 months and stable prostate specific antigen (PSA) are eligible for the study. Note: The investigator should make every appropriate effort to exclude the possibility of prostate cancer, including consideration of prostate biopsy in any subject with a known abnormal PSA. Criteria Based Upon Diagnostic Assessments

- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody

result within 3 months of screening;

- A positive pre-study drug/alcohol screen.

- A positive test for Human Immunodeficiency Virus (HIV) antibody. Other Criteria

- Where participation in the study would result in donation of blood or blood products

in excess of 500 mL within a 56 day period.

- The subject has participated in a clinical trial and has received an investigational

product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

- Exposure to more than four new chemical entities within 12 months prior to the first

dosing day.

- Unable to refrain from the use of prescription or non-prescription drugs, including

vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.

Locations and Contacts

GSK Investigational Site, Baltimore, Maryland 21225, United States
Additional Information

Starting date: July 2014
Last updated: April 16, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017